64.03
price down icon0.31%   -0.20
after-market  After Hours:  64.13  0.10   +0.16%
loading
Lemaitre Vascular Inc stock is currently priced at $64.03, with a 24-hour trading volume of 73,547. It has seen a -0.31% decreased in the last 24 hours and a -3.63% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $63.81 pivot point. If it approaches the $64.84 resistance level, significant changes may occur.
Previous Close:
$64.23
Open:
$63.72
24h Volume:
73,547
Market Cap:
$1.44B
Revenue:
$193.48M
Net Income/Loss:
$30.11M
P/E Ratio:
52.92
EPS:
1.21
Net Cash Flow:
$29.49M
1W Performance:
+1.57%
1M Performance:
-3.63%
6M Performance:
+29.30%
1Y Performance:
+16.65%
1D Range:
Value
$63.12
$64.67
52W Range:
Value
$44.27
$74.64

Lemaitre Vascular Inc Stock (LMAT) Company Profile

Name
Name
Lemaitre Vascular Inc
Name
Phone
781-221-2266
Name
Address
63 Second Avenue, Burlington, MA
Name
Employee
400
Name
Twitter
@LMAT_Vascular
Name
Next Earnings Date
2024-05-02
Name
Latest SEC Filings
Name
LMAT's Discussions on Twitter

Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-06-24 Resumed KeyBanc Capital Markets Sector Weight
Oct-23-23 Initiated JMP Securities Mkt Outperform
Sep-06-23 Initiated Oppenheimer Outperform
Aug-03-23 Downgrade Jefferies Buy → Hold
May-03-23 Upgrade Barrington Research Mkt Perform → Outperform
Oct-28-22 Downgrade Barrington Research Outperform → Mkt Perform
Sep-16-21 Initiated Jefferies Buy
Feb-12-21 Initiated KeyBanc Capital Markets Sector Weight
Mar-16-20 Upgrade Sidoti Neutral → Buy
Oct-24-19 Downgrade First Analysis Sec Strong Buy → Outperform
Oct-24-19 Upgrade Lake Street Hold → Buy
Oct-14-19 Upgrade First Analysis Sec Outperform → Strong Buy
Jul-25-19 Reiterated Barrington Research Outperform
Jul-25-19 Upgrade First Analysis Sec Neutral → Outperform
Oct-08-18 Upgrade Barrington Research Mkt Perform → Outperform
Oct-08-18 Upgrade ROTH Capital Neutral → Buy
Jun-08-18 Resumed ROTH Capital Buy
Apr-26-18 Downgrade Stifel Buy → Hold
Apr-26-18 Upgrade The Benchmark Company Hold → Buy
Oct-27-17 Downgrade First Analysis Sec Overweight → Equal-Weight
Oct-27-17 Downgrade The Benchmark Company Buy → Hold
Jul-10-17 Downgrade Canaccord Genuity Buy → Hold
Jul-10-17 Downgrade The Benchmark Company Buy → Hold
Mar-21-17 Initiated First Analysis Sec Overweight
Feb-22-17 Downgrade Barrington Research Outperform → Mkt Perform
Sep-22-16 Downgrade Sidoti Buy → Neutral
Jul-28-16 Reiterated Barrington Research Outperform
Feb-25-16 Reiterated Barrington Research Outperform
View All

Lemaitre Vascular Inc Stock (LMAT) Financials Data

Lemaitre Vascular Inc (LMAT) Revenue 2024

LMAT reported a revenue (TTM) of $193.48 million for the quarter ending December 31, 2023, a +19.69% rise year-over-year.
loading

Lemaitre Vascular Inc (LMAT) Net Income 2024

LMAT net income (TTM) was $30.11 million for the quarter ending December 31, 2023, a +45.89% increase year-over-year.
loading

Lemaitre Vascular Inc (LMAT) Cash Flow 2024

LMAT recorded a free cash flow (TTM) of $29.49 million for the quarter ending December 31, 2023, a +33.13% increase year-over-year.
loading

Lemaitre Vascular Inc (LMAT) Earnings per Share 2024

LMAT earnings per share (TTM) was $1.34 for the quarter ending December 31, 2023, a +44.09% growth year-over-year.
loading
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.
$167.86
price down icon 2.00%
medical_instruments_supplies TFX
$211.17
price up icon 0.03%
medical_instruments_supplies COO
$90.20
price down icon 1.61%
$76.71
price down icon 0.62%
medical_instruments_supplies BAX
$40.93
price down icon 0.22%
medical_instruments_supplies RMD
$183.78
price down icon 0.24%
Cap:     |  Volume (24h):